Citations

Showing 10 of 108135 citations.

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
André, Fabrice , Ismaila, Nofisat , Henry, N. Lynn , Somerfield, Mark R. , Hammond, M. Elizabeth, Kuderer, Nicole M. , Liu, Minetta C. , Poznak, Catherine Van , Henry, N Lynn , André, Fabrice , Bast, Robert C. , Barlow, William E. , Collyar, Deborah , Wolff, Antonio C. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | May 31, 2019 | Volume: 37 | Issue: 22 | Pages: 1956-1964

10.1200/jco.19.00945 | PMID 31150316 Get It

PURPOSE This focused update addresses the use of Onco type DX in guiding decisions on the use of adjuvant systemic therapy. METHODS ASCO uses a signals approach to facilitate guideline updating. For this focused update, the publication of the Trial Assigning Individualized Options for Treatment (TAILORx) evaluating noninferiority of endocrine therapy alone versus chemoendocrine therapy for invasive disease–free survival in women with Onco type DX scores provided a signal. An expert panel reviewed the results of TAILORx along with other published literature on the Onco type DX assay to assess for evidence of clinical utility. UPDATED RECOMMENDATIONS For patients with hormone receptor–positive, axillary node–negative breast cancer whose tumors have Onco type DX recurrence scores of less than 26, there is little to no benefit from chemotherapy, especially for patients older than age 50 years. Clinicians may recommend endocrine therapy alone for women older than age 50 years. For patients 50 years of age or younger with recurrence scores of 16 to 25, clinicians may offer chemoendocrine therapy. Patients with recurrence scores greater than 30 should be considered candidates for chemoendocrine therapy. Based on informal consensus, the panel recommends that oncologists may offer chemoendocrine therapy to these patients with recurrence scores of 26 to 30. Additional information can be found at www.asco.org/breast-cancer-guidelines .
Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis
Dempsey, Timothy , Sangaralingham, Lindsey R. , Yao, Xiaoxi , Sanghavi, Darshak , Shah, Nilay D. , Dempsey, Timothy M , Yao, Xiaoxi , Limper, Andrew H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 31, 2019 | Volume: 200 | Issue: 2 | Pages: 168-174

10.1164/rccm.201902-0456oc | PMID 31150266 Get It

Abstract Rationale Since their approval, there has been no real-world or randomized trial evidence evaluating the effect of the antifibrotic medications pirfenidone and nintedanib on clinically important outcomes such as mortality and hospitalizations. Objectives To evaluate the clinical effectiveness of the antifibrotic medications pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis. Methods Using a large U.S. insurance database, we identified 8,098 patients with idiopathic pulmonary fibrosis between October 1, 2014 and March 1, 2018. A one-to-one propensity score–matched cohort was created to compare patients treated with antifibrotic medications (n = 1,255) with those not on treatment (n = 1,255). The primary outcome was all-cause mortality. The secondary outcome was acute hospitalizations. Subgroup analyses were performed to evaluate mortality differences by drug. Measurements and Main Results The use of antifibrotic medications was associated with a decreased risk of all-cause mortality (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62–0.98; P value = 0.034). However, this association was present only through the first 2 years of treatment. There was also a decrease in acute hospitalizations in the treated cohort (HR, 0.70; 95% CI, 0.61–0.80; P value <0.001). There was no significant difference in all-cause mortality between patients receiving pirfenidone and those on nintedanib (HR, 1.14; 95% CI, 0.79–1.65; P = 0.471). Conclusions Among patients with idiopathic pulmonary fibrosis, antifibrotic agents may be associated with a lower risk of all-cause mortality and hospitalization compared with no treatment. Future research should test the hypothesis that these treatments reduce early, but not long-term, mortality as demonstrated in our study.
Baseball Pitchers’ Perceived Effort Does Not Match Actual Measured Effort During a Structured Long-Toss Throwing Program
Melugin, Heath P. , Conte, Stan, Fealy, Stephen A., D’Angelo, John, Larson, Dirk R. , Fleisig, Glenn S. , Dines, Joshua S. , Camp, Christopher L.

Mayo Clinic

The American Journal of Sports Medicine | May 31, 2019 | Volume: 47 | Issue: 8 | Pages: 1949-1954

10.1177/0363546519850560 | PMID 31150269 Get It

Background: During rehabilitation throwing programs, baseball players are commonly asked to throw at reduced levels of effort (ie, 50% effort, 75% effort, etc) to moderate stress to healing tissues. It is currently unknown how changes in players’ perceived exertion compares with changes in actual exertion during structured long-toss programs. Purpose: To determine whether decreased effort correlates with decreased throwing metrics, whether metrics decrease proportionally with reductions in perceived effort, and to quantify intrathrower variability. Study Design: Descriptive laboratory study. Methods: Sixty male high school and collegiate baseball pitchers participated in a structured throwing program. A motusBASEBALL sleeve was worn by all players, which measured elbow varus torque, arm velocity, arm slot, and shoulder rotation. Ball velocity was measured with a radar gun. Each pitcher threw 5 throws a distance of 120 ft with 3 efforts: maximum effort, 75% effort, and 50% effort. Throwing metrics were compared among the 3 levels of effort to see if each 25% decrease resulted in proportional decreases in elbow varus torque and ball velocity. Intrathrower variability was determined for each throwing metric at each degree of effort. Results: All throwing metrics decreased as players decreased their perceived effort ( P < .001). However, these observed decreases were much smaller in magnitude than the decreases in perceived effort. During the 75% effort throws, elbow varus torque was only reduced to 93% of maximum and velocity dropped to 86% of maximum. Similarly, for the 50% effort throws, elbow varus torque remained 87% of max effort torque, while velocity remained 78% of max. Intrathrower reliability was considered excellent for most metrics (intraclass correlation coefficient, >0.75). Conclusion: For every 25% decrease in perceived effort, elbow varus torque only decreased 7% and velocity only decreased 11%. Thus, when players throw at what they perceive to be reduced effort, their actual throwing metrics do not decrease at the same rate as their perceived exertion. Clinical Relevance: Measured effort decreased with decreasing perceived effort, but these were not proportional. This has significant implications for physical therapists, physicians, trainers, coaches, and athletes to understand and monitor elbow stress during the rehabilitation process.
Multiplanar Loading of the Knee and Its Influence on Anterior Cruciate Ligament and Medial Collateral Ligament Strain During Simulated Landings and Noncontact Tears
Bates, Nathaniel A. , Schilaty, Nathan D. , Nagelli, Christopher V. , Krych, Aaron J. , Hewett, Timothy E. , Krych, Aaron J , Schilaty, Nathan D , Bates, Nathaniel A

Mayo Clinic

The American Journal of Sports Medicine | May 31, 2019 | Volume: 47 | Issue: 8 | Pages: 1844-1853

10.1177/0363546519850165 | PMID 31150273 Get It

Background: Anterior cruciate ligament (ACL) tears and concomitant medial collateral ligament (MCL) injuries are known to occur during dynamic athletic tasks that place combinatorial frontal and transverse plane loads on the knee. A mechanical impact simulator that produces clinical presentation of ACL injury allows for the quantification of individual loading contributors leading to ACL failure. Purpose/Hypothesis: The objective was to delineate the relationship between knee abduction moment, anterior tibial shear, and internal tibial rotation applied at the knee and ACL strain during physiologically defined simulations of impact at a knee flexion angle representative of initial contact landing from a jump. The hypothesis tested was that before ACL failure, abduction moment would induce greater change in ACL strain during landing than either anterior shear or internal rotation. Study Design: Controlled laboratory study. Methods: Nineteen cadaveric specimens were subjected to simulated landings in the mechanical impact simulator. During simulations, external knee abduction moment, internal tibial rotation moment, and anterior tibial shear loads were derived from a previously analyzed in vivo cohort and applied to the knee in varying magnitudes with respect to injury risk classification. Implanted strain gauges were used to track knee ligament displacement throughout simulation. Kruskal-Wallis tests were used to assess strain differences among loading factors, with Wilcoxon each pair post hoc tests used to assess differences of magnitude within each loading. Results: Each loading factor significantly increased ACL strain ( P < .005). Within factors, the high-risk magnitude of each factor significantly increased ACL strain relative to the baseline condition ( P≤ .002). However, relative to knee abduction moment specifically, ACL strain increased with each increased risk magnitude ( P≤ .015). Conclusion: Increased risk levels of each load factor contributed to increased levels of ACL strain during a simulated jump landing. The behavior of increased strain between levels of increased risk loading was most prevalent for changes in knee abduction moment. This behavior was observed in the ACL and MCL. Clinical Relevance: Knee abduction moment may be the predominant precursor to ACL injury and concomitant MCL injury. As knee abduction occurs within the frontal plane, primary preventative focus should incorporate reduction of frontal plane knee loading in landing and cutting tasks, but secondary reduction of transverse plane loading could further increase intervention efficacy. Constraint of motion in these planes should restrict peak ACL strain magnitudes during athletic performance.
Mutations in Both the Surface and Transmembrane Envelope Glycoproteins of the RAV-2 Subgroup B Avian Sarcoma and Leukosis Virus Are Required to Escape the Antiviral Effect of a Secreted Form of the TvbS3 Receptor †
Yin, Xueqian , Melder, Deborah C., Payne, William S., Dodgson, Jerry B., Federspiel, Mark J.

Mayo Clinic

Viruses | May 31, 2019 | Volume: 11 | Issue: 6 | Pages: 500

10.3390/v11060500 | PMID 31159208 Get It

The subgroup A through E avian sarcoma and leukosis viruses ASLV(A) through ASLV(E) are a group of highly related alpharetroviruses that have evolved to use very different host protein families as receptors. We have exploited genetic selection strategies to force the replication-competent ASLVs to naturally evolve and acquire mutations to escape the pressure on virus entry and yield a functional replicating virus. In this study, evolutionary pressure was exerted on ASLV(B) virus entry and replication using a secreted for of its Tvb receptor. As expected, mutations in the ASLV(B) surface glycoprotein hypervariable regions were selected that knocked out the ability for the mutant glycoprotein to bind the sTvbS3-IgG inhibitor. However, the subgroup B Rous associated virus 2 (RAV-2) also required additional mutations in the C-terminal end of the SU glycoprotein and multiple regions of TM highlighting the importance of the entire viral envelope glycoprotein trimer structure to mediate the entry process efficiently. These mutations altered the normal two-step ASLV membrane fusion process to enable infection.
Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019
Miglioretti, Diana L. , Vachon, Celine M. , Miglioretti, Diana L , Kerlikowske, Karla , Vachon, Celine M.

Mayo Clinic

JAMA | May 31, 2019 | Volume: 322 | Issue: 1 | Pages: 69

10.1001/jama.2019.6247 | PMID 31150040 Get It

060 Women’s Perspectives on Aging and Menopause and Symptom Treatment
Kingsberg, Sheryl A. , Graham, S., Bernick, Brian , Mirkin, Sebastián, Faubion, Stephanie S. , Larkin, Lisa

Mayo Clinic

The Journal of Sexual Medicine | May 31, 2019 | Volume: 16 | Issue: Supplement_3 | Pages: S22-S23

10.1016/j.jsxm.2019.03.505 Get It

059 What are the Associations of Body Mass Index, Sexual Dysfunction and Mood in Midlife Women?
Fairbanks, Flávia, Kapoor, Ekta , Faubion, Stephanie S. , Mara, Kristin C.

Mayo Clinic

The Journal of Sexual Medicine | May 31, 2019 | Volume: 16 | Issue: Supplement_3 | Pages: S22-S22

10.1016/j.jsxm.2019.03.504 Get It

Targeting the tumor microenvironment in pancreatic ductal adenocarcinoma
Pandey, Veethika , Störz, Peter

Mayo Clinic

Expert Review of Anticancer Therapy | May 31, 2019 | Volume: 19 | Issue: 6 | Pages: 473-482

10.1080/14737140.2019.1622417 | PMID 31148495 Get It

Ibrutinib induced acute tubular injury: A case series and review of the literature
Manohar, Sandhya , Bansal, Anip, Wanchoo, Rimda, Sakhiya, Vipulbhai, Lucia, Scott, Jhaveri, Kenar D. , Jhaveri, Kenar D

Mayo Clinic

American Journal of Hematology | May 31, 2019 | Volume: 94 | Issue: 9 | Pages: No page available

10.1002/ajh.25546 | PMID 31148235 Get It